Research Stories
Discover how POG research can lead to new insights about cancer
Explore stories about POG research and the discoveries that are helping us better understand how cancers develop, behave, and respond to treatment.
When the DNA didn’t have the answer, the RNA did
How POG used gene expression to uncover a treatment option for a child with a rare cancer
At just 8 years old, a child was diagnosed with a rare sarcoma in the brain. After intensive treatment, including chemotherapy, a stem cell transplant and radiation, the cancer disappeared for two years.
Then it came back.
This time, the cancer had spread to the lungs, with numerous tumours developing throughout both lungs. The child enrolled in the Personalized OncoGenomics (POG) study, where the tumour was analyzed using whole-genome and RNA sequencing to look for clues that could help guide treatment.
Looking beyond DNA mutations
The genomic analysis identified a rare genetic fusion called EWSR1-ATF1, which helped characterize the biology of the tumour. However, there was no available treatment that could directly target this fusion.
Several other genetic changes were found, but none provided a clear treatment option.
This is where the RNA sequencing became particularly important.
Instead of only asking “What mutations does this cancer have?”, the POG team also asked:
“Which genes are unusually active in this tumour?”
The analysis showed unusually high activity in the IL6/JAK/STAT3 signaling pathway, a pathway involved in communication between cells that can also contribute to cancer growth.
The team found particularly high expression of JAK1, along with several other genes involved in this pathway. These findings were confirmed by comparing the tumour's RNA profile with thousands of other cancers, helping distinguish signals coming from the tumour itself from those related to the fact that the cancer had spread to the lungs.
Turning a genomic clue into a treatment idea
The POG molecular tumour board (a meeting consisting of genomic analysts and medical oncologists/professionals) considered whether blocking this pathway could slow the cancer.
Two possible treatment approaches were identified: targeting JAK with the drug ruxolitinib, or targeting ALK with crizotinib.
Ruxolitinib was selected because it acted further downstream in the pathway and could potentially interfere with signals arising from both the tumour's genetic fusion and its activated receptor signalling pathways. There was also information available to support its use in children.
This was an experimental treatment decision based on the tumour's molecular characteristics.
A rapid change
When treatment began, the child was extremely unwell, experiencing severe nausea and fatigue and spending much of the day in bed.
Within just one week of starting ruxolitinib, the change was striking.
The nausea disappeared, and energy levels improved dramatically. The child's ability to function improved from a Lansky performance score of 60 to 90–100, where the improvement was sustained for approximately five months.
Imaging also showed that the rapidly growing lung tumours had stabilized.
Eventually, one lung tumour began growing while most of the others remained stable. Ruxolitinib was stopped and the growing tumour was treated with radiation.
But within two months, the child's symptoms returned and the other lung tumours began progressing.
The family requested that ruxolitinib be restarted to improve quality of life. Once again, the child experienced a dramatic improvement in symptoms, and the cancer remained stable for a prolonged period.
Treatment eventually had to be reduced because of low blood counts, after which the cancer progressed. The child died 23 months after the cancer had returned.
Why this case matters
This case illustrates why looking at both DNA and RNA can be important in precision oncology.
The tumour did not contain an obvious DNA mutation that could be matched to an available treatment. Instead, RNA sequencing revealed that a particular signalling pathway was unusually active. By comparing the tumour's gene expression pattern with thousands of other cancers, the POG team was able to identify a potential treatment strategy that would not have been apparent from DNA sequencing alone.
The response also showed the complexity of cancer. Most of the lung tumours responded or remained stable, while one tumour became resistant. This suggests that different cancer cells within the same patient can behave differently and may respond differently to treatment.
For the POG program, this case demonstrates the value of looking beyond individual mutations to understand what a patient's cancer is actually doing, and using that information to generate new possibilities for treatment.
Read the paper here: https://pmc.ncbi.nlm.nih.gov/articles/PMC6675034/
Finding an Unexpected Treatment Option Through Genomics
A 67-year-old woman was diagnosed with colorectal cancer and initially received chemotherapy. Unfortunately, treatment caused significant side effects, and her cancer later returned. Over the next several years, the cancer came back in different areas despite chemotherapy, radiation and surgery.
After 4 years from the initial diagnosis, the cancer had become difficult to treat, and standard treatment options were limited. At this point, the patient took part in the Personalized OncoGenomics (POG) program at BC Cancer.
Looking deeper into the cancer
The POG research team at Canada’s Michael Smith Genome Sciences Centre performed whole-genome and transcriptome sequencing on a sample of the patient's tumour. This allowed them to look at the cancer DNA and RNA to determine which genes were especially active in the tumour.
The analysis revealed thousands of genetic changes, including changes showing that the cancer had problems repairing damaged DNA. But one finding stood out to the scientists doing the complicated analysis.
Two genes, called FOS and JUN, were much more active than expected. These genes work together as part of a group called the AP-1 complex, which can influence how cancer cells grow and survive.
Rather than simply identifying a genetic change, the team used these findings to ask a different question: What might be driving this activity, and could it be blocked?
An unexpected idea
The researchers found that the AP-1 complex can be activated by a biological system called the renin–angiotensin system, which is best known for helping regulate blood pressure.
This led to an unexpected treatment idea. They would recommend trying a medication that blocks this system.
The patient began taking irbesartan, a medication commonly used to treat high blood pressure.
Their response was dramatic. Within just five weeks, the patient's tumour marker had fallen from 18 to 3.1, and scans showed that almost all visible signs of active cancer had disappeared. The response remained strong for at least 10 months in the published case.
Why this matters
This tumor analysis showed that personalized genomics can involve much more than looking for a single mutation and matching it to a drug.
By combining information from the tumour's DNA and RNA, the POG team was able to identify an unusual pattern of gene activity, connect it to a biological pathway, and develop a potential treatment strategy that would not have been obvious from standard testing.
The findings also demonstrate the potential of drug repurposing, which explores whether an existing medication might have another use in cancer treatment.
Importantly, this was a single patient's experience, and irbesartan is not a standard treatment for colorectal cancer. It does show how comprehensive genomic analysis can generate unexpected ideas and help researchers understand an individual patient's cancer.
For the POG program, this is an example of the kinds of questions whole-genome and transcriptome analysis can help us explore: What is making this particular cancer behave the way it does, and is there a clue that could point us toward a different way of treating it?
Read the paper here: https://doi.org/10.1093/annonc/mdw060
An Extraordinary Response to Immunotherapy
When a 61-year-old woman was diagnosed with melanoma of the eye, there was no sign that the cancer had spread. She received radiation treatment and continued with regular follow-up scans.
About a year later, doctors discovered that the cancer had spread to several parts of her body, including her liver, lungs, bones and lymph nodes. This type of eye cancer, called uveal melanoma, can be difficult to treat once it spreads.
The patient began treatment with immunotherapy, which works by helping the immune system recognize and attack cancer cells. She was treated with two immunotherapy drugs, ipilimumab and nivolumab.
Many metastatic uveal melanoma patients do not respond well to immunotherapy, but this patient’s response was remarkable.
Over the following months, almost all of the cancer disappeared. One tumour in the liver remained, but it also became smaller and less active. After targeted radiation of this remaining tumour, scans showed no evidence of active cancer. The patient remained in complete remission for more than four years after starting immunotherapy.
Looking for clues in the tumour
Of course, the research team wondered why this patient had such a strong response to immunotherapy, which was unusual for most metastatic uveal melanoma patients. What was different about this tumor, why was it so sensitive to treatment?
By the time the researchers were able to obtain a tumour sample, most of the cancer had already disappeared. The remaining liver tumour was therefore an opportunity to look closely at what was happening inside the cancer after treatment.
As part of the Personalized Oncogenomics (POG) research study using whole-genome and transcriptome analysis, the team examined the tumour's DNA and RNA to look for clues about how the cancer was interacting with the immune system.
The analysis revealed several changes in genes involved in immune responses. The tumour also contained unusually high levels of plasma cells, a type of immune cell that can produce antibodies. These cells were more common in this tumour than in other uveal melanoma samples studied by the researchers.
The patient also developed widespread vitiligo, a condition that causes patches of skin to lose their colour, during immunotherapy. Although vitiligo can be a side effect of treatment, it may also be a sign that the immune system has become highly active against pigment-producing cells. Some of the genetic differences found in the patient's blood were also linked to autoimmune conditions and vitiligo.
What can we learn from one exceptional response?
The researchers cannot say for certain which of these factors caused the patient's exceptional response. However, the findings provide clues about how the immune system may have helped control a cancer that usually responds poorly to immunotherapy.
This tumor demonstrates how whole-genome and transcriptome analysis can help researchers investigate the biology behind an unexpected treatment response. By looking at both the cancer's genetic information and how genes are being used, POG researchers can uncover clues about the complex relationship between a tumour and the patient's immune system.
Studying exceptional responses like this may help researchers better understand why some patients respond so well to treatment. In the future, this work could help identify which patients are most likely to benefit from immunotherapy.
Read the paper here: https://www.ovid.com/10.1097/CMR.0000000000000810
When Treatment Exceeds Expectations
A 67-year-old man was diagnosed with pancreatic cancer that had spread to his liver. He also had an inherited change in a gene called BRCA1, which plays an important role in repairing damaged DNA.
Knowing that BRCA1 changes can make some cancers more sensitive to certain chemotherapy drugs, his care team treated him with a combination of chemotherapy called FOLFIRINOX . The response was remarkable. Within just a few months, scans showed that the cancer had disappeared, and the patient continued to do well on treatment for more than a year.
But there was a puzzle.
When researchers looked at the cancer's DNA, they did not see the extent of the DNA damage normally associated with BRCA1-related cancers. If the cancer did not appear to have a high level of DNA damage, why had it responded so well to treatment?
Looking at the cancer over time
As part of the Personalized Oncogenomics (POG) research study, the team used whole-genome (DNA) and transcriptome (RNA) sequencing to examine tumour samples taken at different points in the cancer's development. This allowed them to look not only at what genetic changes were present, but also at when those changes may have occurred.
The analysis showed that changes linked to problems repairing DNA were becoming more common as the cancer developed and spread. This suggested that the DNA repair problem was becoming worse over time, even though the overall amount of DNA damage in the tumour was still relatively low.
This helped explain why the patient's cancer may have been particularly sensitive to FOLFIRINOX: the tumour appeared to have an active DNA repair problem, even though there was not yet a large amount of accumulated DNA damage.
Why does this matter?
This study showed that a tumour's genetic information is not necessarily a snapshot of one disease that does not change. Cancer evolves over time. Looking at when genetic changes happen may provide important information about how a tumour is behaving and how it may respond to treatment.
For the POG program, this is an example of how whole-genome and transcriptome analysis can help researchers dive deeper into a patient's cancer and uncover clues that may not be obvious from a single genetic test. While one patient's experience cannot predict how another patient will respond, studying tumors like this can help us learn more about how cancers evolve and how genomic information could contribute to personalized cancer care.
Read the paper here: https://ascopubs.org/doi/10.1200/PO.18.00057